Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged≥ 65 years …
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged≥ 65 years …
ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic …
P Ghia, A Pluta, M Wach, D Lysak, T Kozak… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …
[HTML][HTML] Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia
TD Shanafelt, XV Wang, NE Kay… - … England Journal of …, 2019 - Mass Medical Soc
Background Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared
with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in …
with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in …
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
T Wen, J Wang, Y Shi, H Qian, P Liu - Leukemia, 2021 - nature.com
Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
[HTML][HTML] Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
JA Woyach, AS Ruppert, NA Heerema… - … England Journal of …, 2018 - Mass Medical Soc
Background Ibrutinib has been approved by the Food and Drug Administration for the
treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has …
treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has …
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
Background The BCL2 inhibitor venetoclax has shown activity in patients with chronic
lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with …
lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with …
Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects
HY Estupiñán, A Berglöf, R Zain… - Frontiers in cell and …, 2021 - frontiersin.org
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this
first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3+ 3 dose …
first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3+ 3 dose …
Ibrutinib and venetoclax for first-line treatment of CLL
N Jain, M Keating, P Thompson… - … England Journal of …, 2019 - Mass Medical Soc
Background Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of
B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic …
B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic …
Role of Bruton's tyrosine kinase in B cells and malignancies
S Pal Singh, F Dammeijer, RW Hendriks - Molecular cancer, 2018 - Springer
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
signaling that is critical for proliferation and survival of leukemic cells in many B cell …